A novel pathway for arsenic elimination: Human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMA V) and the diglutathione conjugate of monomethylarsonous acid (MMAIII)

Molecular Pharmacology

Volumn 86, Issue 2, 2014, Pages 168-179

  Banerjee, Mayukh ^a   Carew, Michael W ^a   Roggenbeck, Barbara A ^a   Whitlock, Brayden D ^a   Naranmandura, Hua ^b   Le, X Chris ^a   Leslie, Elaine M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; CACODYLIC ACID; DIGLUTATHIONE; DIMETHYLARSINOUS ACID; GLUTATHIONE; METHANEARSONIC ACID; METHOTREXATE; MONOMETHYLARSONOUS ACID; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; UNCLASSIFIED DRUG;

ARTICLE; BASOLATERAL MEMBRANE; CELL POPULATION; CELL PROTECTION; CELL TRANSPORT; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; KIDNEY PROXIMAL TUBULE; LIVER CELL; MEMBRANE VESICLE; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; STABLE EXPRESSION; VECTOR CONTROL;

ARSENIC; ARSENICALS; BIOLOGICAL TRANSPORT; CACODYLIC ACID; CELL LINE; GLUTATHIONE; HEK293 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANOMETALLIC COMPOUNDS;

EID: 84903641783     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.091314     Document Type: Article

References (61)

1. Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, and Ferrin TE et al. (2008) The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther 325:859-868. (Pubitemid 351724335)
2. Borst P, de Wolf C, and van de Wetering K (2007) Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch 453:661-673. (Pubitemid 46192537)
3. Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ, Kuil A, Beijnen JH, Scheffer GL, and Jansen G et al. (2007) The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol 71:240-249. (Pubitemid 46020994)
4. Carew MW and Leslie EM (2010) Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis 31:1450-1455.
5. Carew MW, Naranmandura H, Shukalek CB, Le XC, and Leslie EM (2011) Monomethylarsenic diglutathione transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Drug Metab Dispos 39:2298-2304.
6. Chen C, Slitt AL, Dieter MZ, Tanaka Y, Scheffer GL, and Klaassen CD (2005) Upregulation of Mrp4 expression in kidney of Mrp2-deficient TR- rats. Biochem Pharmacol 70:1088-1095. (Pubitemid 41262084)
7. Chen Z-S, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, and Kruh GD (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62:3144-3150. (Pubitemid 34602407)
8. Cole SP (2014) Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol 54:95-117.
9. Cole SP and Deeley RG (2006) Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci 27:438-446. (Pubitemid 44051570)
10. Cullen WR (2014) Chemical mechanism of arsenic biomethylation. Chem Res Toxicol 27:457-461.
11. Currier JM, Svoboda M, de Moraes DP, Matousek T, Dědina J, and Stýblo M (2011) Direct analysis of methylated trivalent arsenicals in mouse liver by hydride generation-cryotrapping-atomic absorption spectrometry. Chem Res Toxicol 24:478-480.
12. Deeley RG, Westlake C, and Cole SP (2006) Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849-899. (Pubitemid 44033384)
13. Dietrich CG, Ottenhoff R, de Waart DR, and Oude Elferink RP (2001) Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 167:73-81. (Pubitemid 32830948)
14. Dopp E, Hartmann LM, Florea AM, von Recklinghausen U, Pieper R, Shokouhi B, Rettenmeier AW, Hirner AV, and Obe G (2004) Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells. Toxicol Appl Pharmacol 201:156-165. (Pubitemid 39487163)
15. Drobná Z, Walton FS, Harmon AW, Thomas DJ, and Stýblo M (2010) Interspecies differences in metabolism of arsenic by cultured primary hepatocytes. Toxicol Appl Pharmacol 245:47-56.
16. Gailer J, Madden S, Buttigieg GA, Denton MB, and Younis HS (2002) Identification of [(GS)2AsSe]- in rabbit bile by size-exclusion chromatography and simultaneous multielement-specific detection by inductively coupled plasma atomic emission spectroscopy. Appl Organometal Chem 16:72-75.
17. Gong Z, Lu X, Cullen WR, and Le XC (2001) Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J Anal At Spectrom 16:1409-1413. (Pubitemid 34026211)
18. Hipfner DR, Gauldie SD, Deeley RG, and Cole SP (1994) Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 54:5788-5792.
19. Hippler J, Zdrenka R, Reichel RA, Weber DG, Rozynek P, Johnen G, Dopp E, and Hirnera AV (2011) Intracellular, time-resolved speciation and quantification of arsenic compounds in human urothelial and hepatoma cells. J Anal At Spectrom 26:2396-2403.
20. Hubaux R, Becker-Santos DD, Enfield KS, Rowbotham D, Lam S, Lam WL, and Martinez VD (2013) Molecular features in arsenic-induced lung tumors. Mol Cancer 12:20.
21. International Agency for Research on Cancer (2012) A Review of Human Carcinogens: C. Arsenic, Metals, Fibres and Dusts, World Health Organization Press, Lyon, France.
22. Kala SV, Kala G, Prater CI, Sartorelli AC, and Lieberman MW (2004) Formation and urinary excretion of arsenic triglutathione and methylarsenic diglutathione. Chem Res Toxicol 17:243-249. (Pubitemid 38252504)
23. Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS, and Lieberman MW (2000) The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 275:33404-33408.
24. Kalivas JH (1987) Evaluation of volume and matrix effects for the generalized standard addition method. Talanta 34:899-903.
25. Kann S, Huang MY, Estes C, Reichard JF, Sartor MA, Xia Y, and Puga A (2005) Arsenite-induced aryl hydrocarbon receptor nuclear translocation results in additive induction of phase I genes and synergistic induction of phase II genes. Mol Pharmacol 68:336-346. (Pubitemid 41058297)
26. Karin NJ (1999) Cloning of transfected cells without cloning rings. Biotechniques 27:681-682.
27. Keppler D (2011) Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol 201:299-323.
28. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, and Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537-3547. (Pubitemid 27355505)
29. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, and Scheper RJ et al. (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96:6914-6919. (Pubitemid 29274984)
30. Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, Du W, Boyd K, Cheok M, and Nakauchi H et al. (2008) Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 68:4983-4989.
31. Kritharis A, Bradley TP, and Budman DR (2013) The evolving use of arsenic in pharmacotherapy of malignant disease. Ann Hematol 92:719-730.
32. Lau A, Whitman SA, Jaramillo MC, and Zhang DD (2013) Arsenic-mediated activation of the Nrf2-Keap1 antioxidant pathway. J Biochem Mol Toxicol 27:99-105.
33. Lee K, Klein-Szanto AJ, and Kruh GD (2000) Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 92:1934-1940. (Pubitemid 32036924)
34. Leslie EM (2012) Arsenic-glutathione conjugate transport by the human multidrug resistance proteins (MRPs/ABCCs). J Inorg Biochem 108:141-149.
35. Leslie EM, Deeley RG, and Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237. (Pubitemid 40552845)
36. Leslie EM, Haimeur A, and Waalkes MP (2004) Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem 279:32700-32708. (Pubitemid 39014729)
37. Leslie EM, Létourneau IJ, Deeley RG, and Cole SP (2003) Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 42:5214-5224. (Pubitemid 36560417)
38. Li L, Sham YY, Bikadi Z, and Elmquist WF (2011) pH-dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos 39:1478-1485.
39. Loffredo CA, Aposhian HV, Cebrian ME, Yamauchi H, and Silbergeld EK (2003) Variability in human metabolism of arsenic. Environ Res 92:85-91. (Pubitemid 36875703)
40. Mass MJ, Tennant A, Roop BC, Cullen WR, Styblo M, Thomas DJ, and Kligerman AD (2001) Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol 14:355-361. (Pubitemid 32367468)
41. McAleer MA, Breen MA, White NL, and Matthews N (1999) pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J Biol Chem 274:23541-23548.
42. Naranmandura H, Ibata K, and Suzuki KT (2007) Toxicity of dimethylmonothioarsinic acid toward human epidermoid carcinoma A431 cells. Chem Res Toxicol 20:1120-1125. (Pubitemid 47372990)
43. Naujokas MF, Anderson B, Ahsan H, Aposhian HV, Graziano JH, Thompson C, and Suk WA (2013) The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem. Environ Health Perspect 121:295-302.
44. Németi B and Gregus Z (2013) Reduction of dimethylarsinic acid to the highly toxic dimethylarsinous acid by rats and rat liver cytosol. Chem Res Toxicol 26:432-443.
45. Oleschuk CJ, Deeley RG, and Cole SP (2003) Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3. Am J Physiol Gastrointest Liver Physiol 284:G280-G289. (Pubitemid 36120134)
46. Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, and Vasken Aposhian H (2000) Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol 163:203-207. (Pubitemid 30152096)
47. Raab A, Meharg AA, Jaspars M, Genney DR, and Feldmann J (2004) Arsenic-glutathione complexes - their stability in solution and during separation by different HPLC modes. J Anal At Spectrom 19:183-190.
48. Rehman K and Naranmandura H (2012) Arsenic metabolism and thioarsenicals. Metallomics 4:881-892.
49. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, and Keppler D (2003) Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38:374-384. (Pubitemid 36919858)
50. Russel FG, Koenderink JB, and Masereeuw R (2008) Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci 29:200-207.
51. Shen S, Li XF, Cullen WR, Weinfeld M, and Le XC (2013) Arsenic binding to proteins. Chem Rev 113:7769-7792.
52. Sumi D, Fukushima K, Miyataka H, and Himeno S (2011) Alternative splicing variants of human arsenic (13 oxidation state) methyltransferase. Biochem Biophys Res Commun 415:48 -53.
53. Suzuki KT, Tomita T, Ogra Y, and Ohmichi M (2001) Glutathione-conjugated arsenics in the potential hepato-enteric circulation in rats. Chem Res Toxicol 14:1604-1611. (Pubitemid 34016624)
54. Vahter M (2000) Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett 112-113:209-217.
55. Van Aubel RA, Smeets PH, van den Heuvel JJ, and Russel FG (2005) Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288:F327-F333. (Pubitemid 40109516)
56. Villa-Bellosta R and Sorribas V (2010) Arsenate transport by sodium/phosphate cotransporter type IIb. Toxicol Appl Pharmacol 247:36-40.
57. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, and De Clercq E et al. (2000) Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 97:7476-7481. (Pubitemid 30431488)
58. Xu S, Weerachayaphorn J, Cai SY, Soroka CJ, and Boyer JL (2010) Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression. Am J Physiol Gastrointest Liver Physiol 299:G126-G135.
59. Yang HC, Fu HL, Lin YF, and Rosen BP (2012) Pathways of arsenic uptake and efflux. Curr Top Membr 69:325-358.
60. Yehiayan L, Pattabiraman M, Kavallieratos K, Wang X, Boise LH, and Cai Y (2009) Speciation, formation, stability and analytical challenges of human arsenic metabolites. J Anal At Spectrom 24:1397-1405.
61. Yoshino Y, Yuan B, Miyashita SI, Iriyama N, Horikoshi A, Shikino O, Toyoda H, and Kaise T (2009) Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal Bioanal Chem 393:689-697. (Pubitemid 50331982)